A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Latest Information Update: 04 Sep 2024
At a glance
- Drugs Ibrutinib (Primary) ; Itacitinib (Primary) ; Parsaclisib (Primary) ; Ruxolitinib (Primary)
- Indications B-cell leukaemia; B-cell lymphoma
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 06 Oct 2022 Status changed from active, no longer recruiting to recruiting.
- 06 Oct 2022 Planned End Date changed from 10 Jul 2023 to 30 Sep 2024.
- 06 Oct 2022 Planned primary completion date changed from 10 Jul 2023 to 30 Sep 2024.